MX2023002667A - Compuestos y metodos para el tratamiento de infecciones virales. - Google Patents

Compuestos y metodos para el tratamiento de infecciones virales.

Info

Publication number
MX2023002667A
MX2023002667A MX2023002667A MX2023002667A MX2023002667A MX 2023002667 A MX2023002667 A MX 2023002667A MX 2023002667 A MX2023002667 A MX 2023002667A MX 2023002667 A MX2023002667 A MX 2023002667A MX 2023002667 A MX2023002667 A MX 2023002667A
Authority
MX
Mexico
Prior art keywords
viral infection
compounds
methods
coronaviruses
treating viral
Prior art date
Application number
MX2023002667A
Other languages
English (en)
Spanish (es)
Inventor
Ameer E Hassan
Yousef Hasan Ahmad Khalili
Original Assignee
Ameer E Hassan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ameer E Hassan filed Critical Ameer E Hassan
Publication of MX2023002667A publication Critical patent/MX2023002667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023002667A 2020-09-04 2021-09-03 Compuestos y metodos para el tratamiento de infecciones virales. MX2023002667A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074602P 2020-09-04 2020-09-04
US202163142669P 2021-01-28 2021-01-28
PCT/US2021/048991 WO2022051575A2 (en) 2020-09-04 2021-09-03 Compounds and methods for treating viral infection

Publications (1)

Publication Number Publication Date
MX2023002667A true MX2023002667A (es) 2023-05-12

Family

ID=80491477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002667A MX2023002667A (es) 2020-09-04 2021-09-03 Compuestos y metodos para el tratamiento de infecciones virales.

Country Status (7)

Country Link
US (1) US20230346816A1 (cg-RX-API-DMAC10.html)
EP (1) EP4208137A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023541007A (cg-RX-API-DMAC10.html)
CA (1) CA3194024A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002667A (cg-RX-API-DMAC10.html)
TW (1) TW202228730A (cg-RX-API-DMAC10.html)
WO (1) WO2022051575A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202239417A (zh) * 2021-01-29 2022-10-16 艾米爾 E 哈森 預防病毒感染之方法
US20260191887A1 (en) * 2022-04-21 2026-07-09 Therapeutikos, Inc. Methods of treating inflammation
GB2628963A (en) * 2023-02-08 2024-10-16 Univ Of Lincoln Formulations and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533776A (zh) * 2003-03-27 2004-10-06 中国人民解放军第三军医大学 N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用
CA2608651A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
JP5522640B2 (ja) * 2009-10-15 2014-06-18 独立行政法人産業技術総合研究所 シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物
JP5807895B2 (ja) * 2011-02-17 2015-11-10 学校法人慶應義塾 Hcvrna複製抑制剤
EP2696680B1 (en) * 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CN107281199A (zh) * 2017-07-27 2017-10-24 吉林省始祖生物波医学研究院有限公司 N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物

Also Published As

Publication number Publication date
US20230346816A1 (en) 2023-11-02
TW202228730A (zh) 2022-08-01
WO2022051575A3 (en) 2022-04-07
EP4208137A4 (en) 2024-08-28
CA3194024A1 (en) 2022-03-10
WO2022051575A2 (en) 2022-03-10
EP4208137A2 (en) 2023-07-12
JP2023541007A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
WO2022051575A3 (en) Compounds and methods for treating viral infection
MX2022010874A (es) Lactoferrina de uso oral con accion antiviral.
CY1120079T1 (el) Υδατικη συνθεση που περιεχει βρωμεξινη
EA201792429A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
PH12015500355B1 (en) Compounds for the treatment of paramoxyvirus viral infections
EA201890722A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
PH12016500332B1 (en) Antiviral compounds
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201890723A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
MX381538B (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue.
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
CL2011002494A1 (es) Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih).
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
BR112018003086A2 (pt) processo para captura de dióxido de carbono e dessalinação
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
MX2020002151A (es) Compuestos antivirales.
BR112022016117A2 (pt) Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22
MY200606A (en) Cap sterilizer, content filling system, and cap sterilization method
CL2023000699A1 (es) Tratamientos de angioedema
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
BR112014010226A2 (pt) unidades de transcrição e utilização da mesma em vetores de expressão
CL2016000300A1 (es) Métodos terapéuticos
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler